Necati Örmeci1, Murat Taner Gülşen2, Orhan Sezgin3, Sevda Aghayeva4, Mehmet Demir5, Iftihar Köksal6, Rahmet Güner7, Elife Erarslan8, Özgün Ömer Asiller1, Ayhan Balkan2, Serkan Yaraş3, Aysun Çalışkan Kartal1. 1. Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. 2. Department of Gastroenterology, Gaziantep University School of Medicine, Gaziantep, Turkey. 3. Department of Gastroenterology, Mersin University School of Medicine, Mersin, Turkey. 4. Department of Gastroenterology, Azerbaijan Medical University School of Medicine, Baku, Azerbaijan. 5. Department of Gastroenterology, Hatay Mustafa Kemal University School of Medicine, Hatay, Turkey. 6. Department of Gastroenterology, Karadeniz Technical University School of Medicine, Trabzon, Turkey. 7. Department of Infectious Diseases and Clinical Microbiology, Yıldırım Beyazıt University School of Medicine, Ankara, Turkey. 8. Department of Gastroenterology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.
Abstract
BACKGROUND/AIMS: Hepatitis C virus (HCV) infection is a common disease that causes liver cirrhosis, hepatocellular carcinoma, and extra hepatic manifestations with high mortality and morbidity rates. This study aimed to present real-life experiences and results of treatment of HCV infection with direct-acting antiviral agents (DAAs) from the Euro-Asian region, including Turkey and Azerbaijan. MATERIALS AND METHODS: A total of 1224 patients with chronic HCV infection were treated with DAAs in accordance with the international guidelines for the management of HCV infection. The mean age was 58.74±14.75 years, with 713 (58.25%) females. The genotypes of the patients were as follows: genotype 1b, 83.36% (n=1024); genotype 1a, 8.08% (n=99); genotype 2, 2.85% (n=35); genotype 3, 3.34% (n=41); genotype 4, 1.71% (n=21); and combined genotypes, 0.32% (n=4). Approximately 808 patients were treated with sofosbuvir-based DAAs with or without Ribavirin for 12 or 24 weeks, whereas 416 patients were treated with the Paritaprevir, Ombitasvir, Ritonavir.Dasabuvir (PROD) regimen with or without Ribavirin for 12 weeks or 24 weeks. RESULTS: At the end of follow-up examinations, 1183 patients (97.93%) had sustained virological response (SVR), 17 (1.40%) died of reasons unrelated to the treatment regimen, 12 had recurrence after treatment, and 129 (10.67%) had adverse events like anemia, itching, and weakness. CONCLUSION: In this large cohort of HCV-infected patients, treatment with DAAs yielded a high overall SVR rate of 97.93%. DAAs were safe and well-tolerated. Thus, the elimination of HCV infection is no longer a dream worldwide.
BACKGROUND/AIMS: Hepatitis C virus (HCV) infection is a common disease that causes liver cirrhosis, hepatocellular carcinoma, and extra hepatic manifestations with high mortality and morbidity rates. This study aimed to present real-life experiences and results of treatment of HCV infection with direct-acting antiviral agents (DAAs) from the Euro-Asian region, including Turkey and Azerbaijan. MATERIALS AND METHODS: A total of 1224 patients with chronic HCV infection were treated with DAAs in accordance with the international guidelines for the management of HCV infection. The mean age was 58.74±14.75 years, with 713 (58.25%) females. The genotypes of the patients were as follows: genotype 1b, 83.36% (n=1024); genotype 1a, 8.08% (n=99); genotype 2, 2.85% (n=35); genotype 3, 3.34% (n=41); genotype 4, 1.71% (n=21); and combined genotypes, 0.32% (n=4). Approximately 808 patients were treated with sofosbuvir-based DAAs with or without Ribavirin for 12 or 24 weeks, whereas 416 patients were treated with the Paritaprevir, Ombitasvir, Ritonavir.Dasabuvir (PROD) regimen with or without Ribavirin for 12 weeks or 24 weeks. RESULTS: At the end of follow-up examinations, 1183 patients (97.93%) had sustained virological response (SVR), 17 (1.40%) died of reasons unrelated to the treatment regimen, 12 had recurrence after treatment, and 129 (10.67%) had adverse events like anemia, itching, and weakness. CONCLUSION: In this large cohort of HCV-infected patients, treatment with DAAs yielded a high overall SVR rate of 97.93%. DAAs were safe and well-tolerated. Thus, the elimination of HCV infection is no longer a dream worldwide.
Authors: Jordan J Feld; Raoel Maan; Stefan Zeuzem; Alexander Kuo; David R Nelson; Adrian M Di Bisceglie; Michael P Manns; Ken Sherman; Lynn M Frazier; Richard Sterling; Mark Mailliard; Monica Schmidt; Lucy Akushevich; Monika Vainorius; Michael W Fried Journal: Clin Infect Dis Date: 2016-06-19 Impact factor: 9.079
Authors: H Wedemeyer; A S Duberg; M Buti; W M Rosenberg; S Frankova; G Esmat; N Örmeci; H Van Vlierberghe; M Gschwantler; U Akarca; S Aleman; I Balık; T Berg; F Bihl; M Bilodeau; A J Blasco; C E Brandão Mello; P Bruggmann; F Calinas; J L Calleja; H Cheinquer; P B Christensen; M Clausen; H S M Coelho; M Cornberg; M E Cramp; G J Dore; W Doss; M H El-Sayed; G Ergör; C Estes; K Falconer; J Félix; M L G Ferraz; P R Ferreira; J García-Samaniego; J Gerstoft; J A Giria; F L Gonçales; M Guimarães Pessôa; C Hézode; S J Hindman; H Hofer; P Husa; R Idilman; M Kåberg; K D E Kaita; A Kautz; S Kaymakoglu; M Krajden; H Krarup; W Laleman; D Lavanchy; P Lázaro; R T Marinho; P Marotta; S Mauss; M C Mendes Correa; C Moreno; B Müllhaupt; R P Myers; V Nemecek; A L H Øvrehus; J Parkes; K M Peltekian; A Ramji; H Razavi; N Reis; S K Roberts; F Roudot-Thoraval; S D Ryder; R Sarmento-Castro; C Sarrazin; D Semela; M Sherman; G E Shiha; J Sperl; P Stärkel; R E Stauber; A J Thompson; P Urbanek; P Van Damme; I van Thiel; D Vandijck; W Vogel; I Waked; N Weis; J Wiegand; A Yosry; A Zekry; F Negro; W Sievert; E Gower Journal: J Viral Hepat Date: 2014-05 Impact factor: 3.728
Authors: Fred Poordad; Christophe Hezode; Roger Trinh; Kris V Kowdley; Stefan Zeuzem; Kosh Agarwal; Mitchell L Shiffman; Heiner Wedemeyer; Thomas Berg; Eric M Yoshida; Xavier Forns; Sandra S Lovell; Barbara Da Silva-Tillmann; Christine A Collins; Andrew L Campbell; Thomas Podsadecki; Barry Bernstein Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Lisa I Backus; Pamela S Belperio; Troy A Shahoumian; Timothy P Loomis; Larry A Mole Journal: Hepatology Date: 2016-06-07 Impact factor: 17.425
Authors: H Omar; W El Akel; T Elbaz; M El Kassas; K Elsaeed; H El Shazly; M Said; M Yousif; A A Gomaa; A Nasr; M AbdAllah; M Korany; S A Ismail; M K Shaker; W Doss; G Esmat; I Waked; Y El Shazly Journal: Aliment Pharmacol Ther Date: 2017-11-29 Impact factor: 8.171
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245